SCHEMBL179284

SCHEMBL179284

CC(C)(C)c1cnccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.42
KDM4E B2RXH2 5/20 0.40
HSP90AA1 P07900 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
NAPRT Q6XQN6 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
ALDH1A1 P00352 2/20 0.33
KIF11 P52732 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HPGD P15428 1/20 0.33
BAZ2B Q9UIF8 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31256061 1.00 CYP19A1 (0.42) CYP19A1KDM4EHSP90AA1SMN1; SMN2NPC1
SCHEMBL4630149 0.80 CYP19A1 (0.40) CYP19A1KDM4EHSP90AA1SMN1; SMN2NPC1
SCHEMBL20774860 0.80 CYP19A1 (0.40) CYP19A1KDM4EHSP90AA1SMN1; SMN2NPC1
SCHEMBL9474833 0.80 CYP19A1 (0.48) CYP19A1KDM4EHSP90AA1SMN1; SMN2NPC1
SCHEMBL19573760 0.80 HSP90AA1 (0.42) CYP19A1KDM4EHSP90AA1SMN1; SMN2NPC1
SCHEMBL9589700 0.80 CYP19A1 (0.40) CYP19A1KDM4EHSP90AA1SMN1; SMN2NPC1
SCHEMBL8289716 0.80 CYP19A1 (0.40) CYP19A1KDM4EHSP90AA1SMN1; SMN2NPC1
SCHEMBL85681 0.80 CYP19A1 (0.40) CYP19A1KDM4EHSP90AA1SMN1; SMN2NPC1
SCHEMBL20128883 0.80 CYP19A1 (0.40) CYP19A1KDM4EHSP90AA1SMN1; SMN2NPC1
SCHEMBL28453438 0.80 CYP19A1 (0.44) CYP19A1KDM4EHSP90AA1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1963 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260096585-A1 ORAL COMPOSITION KAO CORPORATION (JP) 2026-04-09 US claimed
EP-4591720-A1 ORAL COMPOSITION Kao Corporation (JP) 2025-07-30 EP claimed
US-20250177275-A1 ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN INHIBITION OF SKIN AGING CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) 2025-06-05 US claimed
US-20250143995-A1 ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN REGULATION OF SKIN PIGMENTATION CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) 2025-05-08 US claimed
WO-2024063038-A1 ORAL COMPOSITION 花王株式会社 2024-03-28 WO claimed
US-20230321122-A1 ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN HAIR GROWTH REGULATION CUTANEON SKIN & HAIR INNOVATIONS GMBH (DE) 2023-10-12 US claimed
WO-2023161050-A1 ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN INHIBITION OF SKIN AGING CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) 2023-08-31 WO claimed
EP-4233833-A1 ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN INHIBITION OF SKIN AGING CUTANEON - Skin & Hair Innovations GmbH (DE) 2023-08-30 EP claimed
WO-2023151931-A1 ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN REGULATION OF SKIN PIGMENTATION CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) 2023-08-17 WO claimed
EP-4226911-A1 ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN REGULATION OF SKIN PIGMENTATION CUTANEON - Skin & Hair Innovations GmbH (DE) 2023-08-16 EP claimed
US-20140179722-A1 Antiperspirant and Deodorant Compositions THE PROCTER & GAMBLE COMPANY (US) 2014-06-26 US claimed
US-20140170194-A1 FRAGRANCE MATERIALS THE PROCTER & GAMBLE COMPANY (US) 2014-06-19 US claimed
WO-2014093807-A1 FRAGRANCE MATERIALS THE PROCTER & GAMBLE COMPANY (US) 2014-06-19 WO claimed
US-20140170101-A1 Antiperspirant and Deodorant Compositions THE PROCTER & GAMBLE COMPANY (US) 2014-06-19 US claimed
CN-103497163-A Synthesis method of dimethyl isobutyl pyrazine PUCHENG YONGFANG FRAGRANCE TECHNOLOGY CO LTD 2014-01-08 CN claimed
US-7820219-B2 Toasted flavor additive FRITO-LAY NORTH AMERICA, INC. (US) 2010-10-26 US claimed
US-7364766-B2 Toasted flavor additive and method of making FRITO-LAY NORTH AMERICA, INC. (US) 2008-04-29 US claimed
US-20080032022-A1 Toasted Flavor Additive FRITO-LAY NORTH AMERICA, INC. 2008-02-07 US claimed
WO-2005039297-A1 TOASTED FLAVOR ADDITIVE FRITO-LAY NORTH AMERICA, INC. (US) 2005-05-06 WO claimed
US-20050079269-A1 made by cooking whole corn kernels in a solution of lime and water FRITO-LAY NORTH AMERICA, INC. 2005-04-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140170101-A1 Antiperspirant and Deodorant Compositions LPO, GPX4, DEK CYP19A1 1807/4885KDM4E 1936/4885HSP90AA1 1846/4885
US-20260096585-A1 ORAL COMPOSITION TAS2R5, TAS2R16, TAS2R45 CYP19A1 3716/4885KDM4E 674/4885HSP90AA1 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.